(0.10%) 5 136.75 points
(0.06%) 38 465 points
(0.18%) 17 878 points
(-0.25%) $83.64
(1.77%) $1.957
(0.37%) $2 356.00
(0.56%) $27.69
(1.66%) $937.45
(-0.15%) $0.933
(-0.32%) $10.99
(-0.30%) $0.798
(1.58%) $93.33
Quarter results today
(bmo 2024-04-29)
Expected move: +/- 13.47%
@ $14.40
发出时间: 24 Apr 2024 @ 03:24
回报率: -6.46%
上一信号: Apr 24 - 00:01
上一信号:
回报率: -0.17 %
Live Chart Being Loaded With Signals
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases...
Stats | |
---|---|
今日成交量 | 2.84M |
平均成交量 | 3.46M |
市值 | 2.08B |
EPS | $0 ( 2024-02-28 ) |
下一个收益日期 | ( $-0.0400 ) 2024-06-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 149.67 |
ATR14 | $0.0120 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Lonial Sagar | Sell | 5 000 | Common Stock |
2024-03-12 | Charney Laurence N | Sell | 22 000 | Common Stock |
2024-02-14 | Power Sean A | Buy | 0 | |
2024-01-05 | Charney Laurence N | Sell | 17 500 | Common Stock |
2024-01-06 | Weiss Michael S | Buy | 1 001 908 | Common Stock |
INSIDER POWER |
---|
83.58 |
Last 94 transactions |
Buy: 12 977 390 | Sell: 1 920 924 |
音量 相关性
TG Therapeutics Inc 相关性 - 货币/商品
TG Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $233.66M |
毛利润: | $219.11M (93.77 %) |
EPS: | $0.0893 |
FY | 2023 |
营收: | $233.66M |
毛利润: | $219.11M (93.77 %) |
EPS: | $0.0893 |
FY | 2022 |
营收: | $2.79M |
毛利润: | $2.52M (90.48 %) |
EPS: | $-1.510 |
FY | 2021 |
营收: | $6.69M |
毛利润: | $5.90M (88.19 %) |
EPS: | $-2.63 |
Financial Reports:
No articles found.
TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。